Switch theme
Sign up to access all valuation multiples
Daewoong Pharmaceutical Co Ltd develops, manufactures and sells prescription drug products. The company's product portfolio comprises products such as Moxicle, Plunazol Cap, Bearcef tab, Newdizime etc. It develops and promotes brands such as Ursa, Nabota, Luphere, Easyef, Cretropin. The company has manufacturing facilities at Hyangnam and Sungnam.
2002
n/a
LTM Revenue $975M
LTM EBITDA $141M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Daewoong Pharmaceutical has a last 12-month revenue of $975M and a last 12-month EBITDA of $141M.
In the most recent fiscal year, Daewoong Pharmaceutical achieved revenue of $969M and an EBITDA of $76.7M.
Daewoong Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Daewoong Pharmaceutical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $937M | $969M | XXX | XXX | XXX |
| Gross Profit | $435M | $469M | XXX | XXX | XXX |
| Gross Margin | 46% | 48% | XXX | XXX | XXX |
| EBITDA | $122M | $76.7M | XXX | XXX | XXX |
| EBITDA Margin | 13% | 8% | XXX | XXX | XXX |
| Net Profit | $28.8M | $82.9M | XXX | XXX | XXX |
| Net Margin | 3% | 9% | XXX | XXX | XXX |
| Net Debt | $229M | $222M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Daewoong Pharmaceutical's stock price is KRW 132300 (or $90).
Daewoong Pharmaceutical has current market cap of KRW 1.52T (or $1.0B), and EV of KRW 2.06T (or $1.4B).
See Daewoong Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.4B | $1.0B | XXX | XXX | XXX | XXX | $3.62 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Daewoong Pharmaceutical has market cap of $1.0B and EV of $1.4B.
Daewoong Pharmaceutical's trades at 1.4x LTM EV/Revenue multiple, and 9.9x LTM EBITDA.
Analysts estimate Daewoong Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Daewoong Pharmaceutical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.4B | XXX | XXX | XXX |
| EV/Revenue | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 18.3x | XXX | XXX | XXX |
| P/E | 61.5x | XXX | XXX | XXX |
| P/E/Growth | 0.4x | XXX | XXX | XXX |
| EV/FCF | -11.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDaewoong Pharmaceutical's NTM/LTM revenue growth is 4%
Daewoong Pharmaceutical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Daewoong Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Daewoong Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Daewoong Pharmaceutical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 8% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -37% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 12% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 17% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 41% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Daewoong Pharmaceutical acquired XXX companies to date.
Last acquisition by Daewoong Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Daewoong Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Daewoong Pharmaceutical founded? | Daewoong Pharmaceutical was founded in 2002. |
| Where is Daewoong Pharmaceutical headquartered? | Daewoong Pharmaceutical is headquartered in South Korea. |
| Who is the CEO of Daewoong Pharmaceutical? | Daewoong Pharmaceutical's CEO is Mr. Seng-ho Jeon. |
| Is Daewoong Pharmaceutical publicy listed? | Yes, Daewoong Pharmaceutical is a public company listed on KRX. |
| What is the stock symbol of Daewoong Pharmaceutical? | Daewoong Pharmaceutical trades under 069620 ticker. |
| When did Daewoong Pharmaceutical go public? | Daewoong Pharmaceutical went public in 2002. |
| Who are competitors of Daewoong Pharmaceutical? | Similar companies to Daewoong Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Daewoong Pharmaceutical? | Daewoong Pharmaceutical's current market cap is $1.0B |
| What is the current revenue of Daewoong Pharmaceutical? | Daewoong Pharmaceutical's last 12-month revenue is $975M. |
| What is the current EBITDA of Daewoong Pharmaceutical? | Daewoong Pharmaceutical's last 12-month EBITDA is $141M. |
| What is the current EV/Revenue multiple of Daewoong Pharmaceutical? | Current revenue multiple of Daewoong Pharmaceutical is 1.4x. |
| What is the current EV/EBITDA multiple of Daewoong Pharmaceutical? | Current EBITDA multiple of Daewoong Pharmaceutical is 9.9x. |
| What is the current revenue growth of Daewoong Pharmaceutical? | Daewoong Pharmaceutical revenue growth between 2023 and 2024 was 3%. |
| Is Daewoong Pharmaceutical profitable? | Yes, Daewoong Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
